Semaglutide reduces kidney disease risk by 24%

A recent study shows that the weight-loss drug semaglutide can reduce the risk of major kidney events by 24% and all-cause mortality by 20% in people with diabetes and chronic kidney disease. This drug targets risk factors like uncontrolled diabetes and obesity. CKD affects 40-50% of elderly diabetics and 10-20% of younger individuals. Semaglutide joins ARBs, SGLT2 inhibitors, and Finerenone as treatments for CKD. Patients with kidney disease should monitor side effects carefully.